Skip to main content

Advertisement

SpringerLink
Log in

Hispidulin Enhances the Anti-Tumor Effects of Temozolomide in Glioblastoma by Activating AMPK

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Glioblastoma is an aggressive malignancy, which is notorious for its poor prognosis. Although Temozolomide (TMZ) has been showed to be an effective chemotherapeutic agent for glioblastoma treatment, the response rate is far from satisfactory. As a natural compound with anti-cancer activity against a variety of cancers, Hispidulin is a good candidate drug for combination therapy. This study is designed to determine whether Hispidulin could potentiate the anti-tumor activity of TMZ in glioblastoma. Cell proliferation and apoptosis were determined by MTT assay and Hoechst staining, respectively. Expression of proteins relevant to apoptosis and proliferation was detected by Western blotting. Our in vitro assays showed that Hispidulin enhanced the anti-tumor activity of TMZ in glioblastoma by both inhibiting cell proliferation and inducing cell apoptosis. The anti-tumor activity of Hispidulin and the enhanced TMZ anti-tumor activity by Hispidulin induced the activation of AMPK signaling pathway. Our results showed that Hispidulin, by activating AMPK, exhibited anti-tumor activity and potentiated the anti-tumor activity of TMZ in glioblastoma. Although further preclinical and clinical studies are needed, this study provides insight for using Hispidulin as a chemosensitizing agent in clinic settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ostrom, Q. T., et al. (2013). CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncology, 15(Suppl 2), ii1–ii56.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Lin, G. S., et al. (2014). STAT3 serine 727 phosphorylation influences clinical outcome in glioblastoma. International Journal of Clinical and Experimental Pathology, 7(6), 3141–3149.

    PubMed Central  PubMed  Google Scholar 

  3. Stupp, R., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987–996.

    Article  CAS  PubMed  Google Scholar 

  4. Quick, A., et al. (2010). Current therapeutic paradigms in glioblastoma. Reviews on Recent Clinical Trials, 5(1), 14–27.

    Article  CAS  PubMed  Google Scholar 

  5. Chamberlain, M. C. (2010). Temozolomide: Therapeutic limitations in the treatment of adult high-grade gliomas. Expert Review of Neurotherapeutics, 10(10), 1537–1544.

    Article  CAS  PubMed  Google Scholar 

  6. Zhang, J., Stevens, M. F., & Bradshaw, T. D. (2012). Temozolomide: Mechanisms of action, repair and resistance. Current Molecular Pharmacology, 5(1), 102–114.

    Article  CAS  PubMed  Google Scholar 

  7. Tentori, L., & Graziani, G. (2009). Recent approaches to improve the antitumor efficacy of temozolomide. Current Medicinal Chemistry, 16(2), 245–257.

    Article  CAS  PubMed  Google Scholar 

  8. Bourdillat, B., et al. (1988). Mechanism of action of hispidulin, a natural flavone, on human platelets. Progress in Clinical and Biological Research, 280, 211–214.

    CAS  PubMed  Google Scholar 

  9. He, L., et al. (2011). Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3 K/Akt/mTOR signaling pathway. Cancer Science, 102(1), 219–225.

    Article  CAS  PubMed  Google Scholar 

  10. Tan, R. X., et al. (1999). Mono- and sesquiterpenes and antifungal constituents from Artemisia species. Planta Medica, 65(1), 64–67.

    Article  CAS  PubMed  Google Scholar 

  11. Yu, C. Y., et al. (2013). Potential Therapeutic Role of Hispidulin in Gastric Cancer through Induction of Apoptosis via NAG-1 Signaling. Evidence-Based Complementary and Alternative Medicine, 2013, 518301.

    PubMed Central  PubMed  Google Scholar 

  12. Gao, H., Wang, H., & Peng, J. (2014). Hispidulin induces apoptosis through mitochondrial dysfunction and inhibition of P13 k/Akt signalling pathway in HepG2 cancer cells. Cell Biochemistry and Biophysics, 69(1), 27–34.

    Article  CAS  PubMed  Google Scholar 

  13. Yang, J. M., et al. (2010). Hispidulin sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by AMPK activation leading to Mcl-1 block in translation. Journal of Agriculture and Food Chemistry, 58(18), 10020–10026.

    Article  CAS  Google Scholar 

  14. Lin, Y. C., et al. (2010). Hispidulin potently inhibits human glioblastoma multiforme cells through activation of AMP-activated protein kinase (AMPK). Journal of Agriculture and Food Chemistry, 58(17), 9511–9517.

    Article  CAS  Google Scholar 

  15. Cheng, H., et al. (2011). In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemotherapy and Pharmacology, 67(3), 637–646.

    Article  CAS  PubMed  Google Scholar 

  16. Huang, H., et al. (2011). Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Letters, 301(2), 221–228.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Chou, T. C., & Talalay, P. (1984). Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27–55.

    Article  CAS  PubMed  Google Scholar 

  18. Kopelovich, L., et al. (2007). The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiology Biomarkers & Prevention, 16(7), 1330–1340.

    Article  CAS  Google Scholar 

  19. Garami, A., et al. (2003). Insulin activation of Rheb, a mediator of mTOR/S6 K/4E-BP signaling, is inhibited by TSC1 and 2. Molecular Cell, 11(6), 1457–1466.

    Article  CAS  PubMed  Google Scholar 

  20. Zhang, J. F., et al. (2007). Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro. Transplant Immunology, 17(3), 162–168.

    Article  CAS  PubMed  Google Scholar 

  21. Romano, M. F., et al. (2004). Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. European Journal of Cancer, 40(18), 2829–2836.

    Article  CAS  PubMed  Google Scholar 

  22. Yuan, Y., et al. (2012). Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. CNS Neuroscience & Therapeutics, 18(7), 536–546.

    Article  CAS  Google Scholar 

  23. Gong, A., et al. (2014). Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level. Cancer Chemotherapy and Pharmacology, 74(3), 531–538.

    Article  CAS  PubMed  Google Scholar 

  24. Kunnumakkara, A. B., et al. (2008). Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clinical Cancer Research, 14(7), 2128–2136.

    Article  CAS  PubMed  Google Scholar 

  25. Saha, A. K., et al. (2006). AMPK regulation of the growth of cultured human keratinocytes. Biochemical and Biophysical Research Communications, 349(2), 519–524.

    Article  CAS  PubMed  Google Scholar 

  26. Motoshima, H., et al. (2006). AMPK and cell proliferation–AMPK as a therapeutic target for atherosclerosis and cancer. Journal of Physiology, 574(Pt 1), 63–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Yu, S. Y., et al. (2009). Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase. Tumour Biology, 30(2), 80–85.

    Article  CAS  PubMed  Google Scholar 

  28. Inoki, K., Zhu, T., & Guan, K. L. (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115(5), 577–590.

    Article  CAS  PubMed  Google Scholar 

  29. Wang, W., & Guan, K. L. (2009). AMP-activated protein kinase and cancer. Acta Physiologica (Oxf), 196(1), 55–63.

    Article  CAS  Google Scholar 

  30. Cheng, S. W., et al. (2004). Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. Journal of Biological Chemistry, 279(16), 15719–15722.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Xijing Hospital of the Fourth Military Medical University, No. 127 West Changle Road, Xi’an, 710032, Shaanxi, People’s Republic of China

    YanGang Wang, WeiPing Liu, XiaoSheng He & Zhou Fei

Authors
  1. YanGang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. WeiPing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. XiaoSheng He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhou Fei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhou Fei.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, Y., Liu, W., He, X. et al. Hispidulin Enhances the Anti-Tumor Effects of Temozolomide in Glioblastoma by Activating AMPK. Cell Biochem Biophys 71, 701–706 (2015). https://doi.org/10.1007/s12013-014-0252-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0252-6

Keywords

Search

Navigation